Invention Grant
- Patent Title: Protein kinase B inhibitors
-
Application No.: US16841820Application Date: 2020-04-07
-
Publication No.: US11236095B2Publication Date: 2022-02-01
- Inventor: Paul David Johnson , Andrew Leach , Richard William Arthur Luke , Zbigniew Stanley Matusiak , Jeffrey James Morris
- Applicant: AstraZeneca AB
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Main IPC: A61P35/04
- IPC: A61P35/04 ; A61K31/519 ; A61P35/00 ; C07D487/04 ; C07D473/34

Abstract:
The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
Public/Granted literature
- US20200239483A1 PROTEIN KINASE B INHIBITORS Public/Granted day:2020-07-30
Information query